The Children’s Leukemia Research Association, Inc., formerly known as the National Leukemia Research Association, was founded in 1965 to find the causes, treatment, and a cure for Leukemia.
We would like to congratulate the 2020 recipients of our research grants. Their advancements in the medical field will bring us closer to a cure. We are so grateful for all of their work!
Click the button below if you would like to see a complete list of all of our previous research grant recipients.
When go to smile.amazon.com, you can choose our nonprofit as a cause to support! With each purchase you make, Amazon will donate a portion of the proceeds to CLRA. The website still operates the same way as Amazon.com, the only difference is that you make a donation every time you shop! Who knew it could be so easy (and free) to donate?
We love to hear back from previous patients we have helped. If you have previously been aided by CLRA, we would love to hear back. Feel free to send an email to us if you are comfortable sharing your story.
The Children's Leukemia Research Association (CLRA) recently awarded a $100,000 grant to Kimberly Stegmaier, MD, co-director of the Pediatric Hematologic Malignancy Program and the Ted Williams Chair at Dana-Farber. Thc CLRA is a longstanding supporter, having awarded more than $660,000 to pediatric leukemia research at the Institute over the last 15 years.
"For years, the CLRA has recognized the extraordinary talent and expertise at Dana-Farber," said Anthony Pasqua, president of the CLRA. "Dr. Stegmaier and her team are making a tremendous impact on cancer medicine, and we are proud to contribute to their success."
With the generous support of the CLRA over the years, Stegmaier and her team have made significant strides into understanding the biology of leukemia, always with an eye toward translating the research into the clinic to directly benefit patients. Stegmaier's research has led to the launch of multiple clinical trials testing SYK inhibitors in patients with acute myeloid leukemia (AML), and to the identification of othcr new possible therapeutic targets in this disease.
"Understanding the biological underpinnings of AML is crucial to developing new therapies," said Stegmaier. "We couldn't do this research without the support of our generous donors."
"Fifty years ago, a child diagnosed with leukemia might live six months," said Pasqua. "Today, the prognosis is far better, but we are not done yet. There is still so much left to do, and the CLRA will continue supporting the search for a cure."